# US 2019/0316202 A1 · Dna methylation in inflammatory disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316202 A1
- Document ID: US20190316202A1
- Status: Published application
- Kind: A1
- Application number: 16/444,850
- Filed: 2019-06-18
- Published: 2019-10-17
- Earliest claimed: 2016-12-19
- Assignees: Indiana University Research and Technology Corporation
- Applicants: Indiana University Research and Technology Corporation
- Inventors: Raghavendra G. MIRMIRA
- Web page: https://patentgrep.com/patent/US20190316202A1

## CPC

- A61P 5/00: Drugs for disorders of the endocrine system
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- G16B 35/20: Screening of libraries
- C12Q 2600/154: Methylation markers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA and chromatin target of PRMT1 (CHTOP).

## Claims

### Claim 1

A method for determining the methylated state of human preproinsulin (INS) and human chromatin target of PRMT1 (CHTOP) DNA in a patient's cell free circulating DNA, said method comprising the steps of
subjecting a DNA sample isolated from a plasma or serum sample recovered from said patient to a bisulfite reaction; and
measuring the methylation state of both preproinsulin and chromatin target of PRMT1 (CHTOP) DNA present in said bisulfite treated DNA sample.

### Claim 2 (depends on 1)

The method of claim 1 wherein unmethylated sequences of both INS and CHTOP are detected in the same DNA sample isolated from said patient.

### Claim 3 (depends on 1)

The method of claim 1 wherein the relative quantities of unmethylated and methylated sequences of INS and CHTOP are determined.

### Claim 4 (depends on 1)

The method of claim 1 wherein the step of measuring comprises
a) analyzing whether a nucleotide located at position −69 from the human preproinsulin (INS) transcriptional start site is cytosine; and
b) analyzing whether a nucleotide located at the CpG site of Chr1:153610817 of the CHTOP gene remains CpG.

### Claim 5 (depends on 2)

The method of claim 2 wherein the DNA sample is contacted with a nucleic acid probe comprising the sequence of AAACCCAAATATTCAC (SEQ ID NO: 13) and a probe comprising the sequence ACCCCTACCACCTAAC (SEQ ID NO: 4).

### Claim 6

A kit for measuring the methylated state of preproinsulin and CHTOP said kit comprising a nucleic acid molecule selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8; SEQ ID NO: 12 and SEQ ID NO: 13.

### Claim 7 (depends on 6)

The kit of claim 6 comprising the nucleotide sequence of SEQ ID NO: 4 and SEQ ID NO: 13.

### Claim 8

A method for determining inflammation in a subject suspected of having inflammation, the method comprising:
amplifying methylated preproinsulin DNA in a sample obtained from the subject suspected of having inflammation;
amplifying unmethylated preproinsulin DNA in a sample obtained from the subject suspected of having inflammation;
comparing the concentration of methylated preproinsulin DNA and unmethylated preproinsulin DNA in the sample with the concentration of methylated preproinsulin DNA and unmethylated preproinsulin DNA in a control; and
determining that the subject has inflammation when the concentration of methylated preproinsulin DNA in the sample is greater than the concentration of methylated preproinsulin DNA in the control.

### Claim 9 (depends on 8)

The method of claim 8, further comprising analyzing whether a nucleotide located at position −69 from the human preproinsulin (INS) transcriptional start site is methylated or unmethylated.

### Claim 10 (depends on 8)

The method of claim 8, further comprising the steps of
amplifying methylated CHTOP DNA in the sample obtained from the subject suspected of having inflammation;
amplifying unmethylated CHTOP DNA in the sample obtained from the subject suspected of having inflammation;
comparing the concentration of methylated CHTOP DNA and unmethylated CHTOP DNA in the sample with the concentration of methylated CHTOP DNA and unmethylated CHTOP DNA in a control.

### Claim 11 (depends on 8)

The method of claim 8, wherein the preproinsulin DNA in the sample is subjected to a bisulfite reaction.

### Claim 12 (depends on 8)

The method of claim 8, wherein the sample is selected from the group consisting of serum, plasma, whole blood, and urine.

### Claim 13 (depends on 8)

The method of claim 8 wherein the inflammation is due to sepsis and detection of the inflammation identifies a subject as having sepsis when the concentration of methylated preproinsulin DNA in the sample is greater than the concentration of methylated preproinsulin DNA in the control.

### Claim 14 (depends on 10)

The method of claim 10, wherein the inflammation is due to sepsis and detection of the inflammation identifies a subject as having sepsis when the concentration of methylated preproinsulin DNA and the concentration of methylated CHTOP DNA in the sample is greater than the respective concentration of methylated preproinsulin DNA and methylated CHTOP DNA in the control.
